Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
ORLANDO, Fla., Sept. 19, 2016 -- Followers of biotechnology stocks and Durable Medical Equipment (DME) companies are often honed in on two driving forces, regulatory approvals and new sales markets. Innovative medical device maker NanoVibronix, Inc, (OTCQB:NAOV) might have just delivered their investors both with a potentially larger opportunity awaiting its own possible approval.
Last week in an announcement that the market may not have fully realized, NanoVibronix reported that they have received clearance to sell their UroShield™ in Canada. The product is effective in preventing Urinary Tract Infections (UTI) in patients with indwelling urinary catheters. According to NanoVibronix, catheter-associated urinary tract infections (CAUTIs) is one of the leading nosocomial complications which cause patient morbidity and mortality. Prolonged urinary catheterization considerably increases the cost of medical care as well as the inconvenience to the patient.
The announcement is notable insofar as it signals approval by a large government health agency (Health Canada) and the allowance into a good sized market north of our border.
Also notable in the September 6, 2016 release is NanoVibronix’s CEO’s remarks regarding the future of UroShield in the much larger American market. CEO William Stern indicated that while the Company is pleased by the approval in Canada that it is also currently conducting a double blinded clinical trial for UroShield™ in the U.S. in order to obtain 510(k) clearance from the U.S. Food and Drug Administration.
With the U.S. population roughly nine times that of neighbor Canada, investors may be wise to follow the NanoVibronix’s news to see if successes in the north continue in the larger opportunity of the American health care market. Meanwhile sales in Canada will accrue to the Company’s collective gross revenue pattern.
About NanoVibronix
NanoVibronix Inc. is a medical device company headquartered in Elmsford, NY with research and development in Nesher, Israel, that is focused on developing medical devices utilizing its proprietary and patented surface acoustic wave ultrasound. The company's groundbreaking technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications. The devices accelerate wound healing and provide pain relief. The devices can also be administered at home, without the assistance of medical professionals. The company's products include PainShield® and WoundShield™, which both have CE Mark. The PainShield™ also has FDA clearance. NanoVibronix's catheter based products include the UroShield™ and NG-Shield™ that are both CE Marked. UroShield reduces pain and prevents infection in urinary catheters. Additional information about the company is available at: www.nanovibronix.com.
About the Emerging Markets Report:
Emerging Markets Report is owned and operated by Emerging Markets Consulting, a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at
http://www.emergingmarketsllc.com/newsletter.php
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom.
EMC is being paid 3000 dollars a month and 9000 shares by NanoVibronix.
Emerging Markets Consulting, LLC Florida Office 15701 State Road 50, Suite #205 Clermont, FL 34711 E-mail: [email protected] Web: www.emergingmarketsllc.com
